Skip to content
Thymopentin
Thymopentin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L03: Immunostimulants
L03A: Immunostimulants
L03AX: Other immunostimulants in atc
L03AX09: Thymopentin
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201157
Liver neoplasmsD008113EFO_1001513C22.011
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTHYMOPENTIN
INNthymopentin
Description
Thymopentin is an oligopeptide.
Classification
Protein
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O
Identifiers
PDB
CAS-ID69558-55-0
RxCUI40230
ChEMBL IDCHEMBL156025
ChEBI ID
PubChem CID451417
DrugBankDB11996
UNII IDO3Y80ZF13F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 541 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9 adverse events reported
View more details